9th Jun 2016 07:40
LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Thursday said it and Swiss drugmaker Basilea Pharmaceutica International Ltd have initiated a managed access programme for isavuconazole, a treatment for fungal infections.
The access programme will be run by Clinigen's Idis Managed Access arm and will allow patients with serious fungal infections in EU states where isavuconazole is not yet commercial available to access the drug via their physicians.
"Invasive fungal infections pose a fatal threat to immuno-compromised patients. It is therefore crucial that new treatment options like isavuconazole are made available and can be accessed by those who need it at the first possible opportunity. As partners to Basilea, Idis MA will leverage its European distribution network and regulatory expertise to deliver this important medicine to individual patients, wherever they are located in Europe," said Clinigen Managing Director Steve Glass.
Clinigen shares were up 0.1% to 550.50 pence Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L